Drug Profile


Alternative Names: HH-GV678

Latest Information Update: 25 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer Jiangsu Hansoh Pharmaceutical; Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Benzamides; Piperazines; Pyridines; Pyrimidines
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic myeloid leukaemia

Most Recent Events

  • 25 Nov 2016 No recent reports on development identified - Phase-III for Chronic myeloid leukaemia (First-line therapy, Newly diagnosed) in China (PO)
  • 30 Jun 2014 Phase-III clinical trials in Chronic myeloid leukaemia (First-line therapy, Newly diagnosed) in China (PO)
  • 01 Aug 2011 Phase-II clinical trials in Chronic myeloid leukaemia in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top